Clinical Trials in Chicago

Showing 3701-3720 of 17,609 trials

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

NCT02052739

The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).

Super-refractory Status Epilepticus

Supernus Pharmaceuticals, Inc.25 participantsStarted Mar 2014

Birmingham, Alabama, United States • Sarasota, Florida, United States • Chicago, Illinois, United States +14 more locations

COMPLETEDPhase 12.2 miles

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

NCT03107988

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy in patients with relapsed/refractory neuroblastoma. The dose escalation phase of this study (Cohort A1) uses a traditional Phase I 3+3 design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 6 patients (Cohort B1), within which ALKi naïve patients will be prioritized, will be initiated. Parallel cohorts will be initiated in adults or patients with large BSA (Cohort A2) and in combination with chemotherapy upon establishing RP2D (Cohort B2).

Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium65 participantsStarted Sep 2017

Los Angeles, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +10 more locations

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Find Trials by Condition in Chicago

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

Alternative Therapies for Improving Physical Function in Individuals With Stroke

Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria

VerTouch Device: A Prospective Randomized Controlled Trial

Testing "SupporT for ADHD and Related Treatment" (START) for Families of Children With ADHD

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

Clinical Utility of Residual Hearing in the Cochlear Implant Ear

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

DFC 004 Biomarkers for Active Diabetic Foot Ulcers

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency

Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System

Treatment Monitoring in Autism Spectrum Disorder (ASD) in Children

Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Development/Testing of SUMMIT: a Tool to Help Patients Manage Pain While Tapering Opioids

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders